Abstract:Pulmonary arterial hypertension (PAH) is a rare and critical cardiovascular disease characterized by increased pulmonary vascular resistance, lesions in the pulmonary arterioles, and a subsequent rise in the right ventricular load, which inevitably leads to right heart failure. Unfortunately, patients with PAH have a poor prognosis, with a median survival time of 2.8 years under traditional drug therapy when there are no targeted pharmaceuticals, earning it the reputation of being a cancer of the cardiovascular system. Patients with PAH face significant challenges. They usually show nonspecific clinical manifestations in the early stages, which often leads to delayed diagnosis and treatment. The majority of the population with PAH in China are young and middle-aged females. Apart from physical difficulties, these patients may have a poor quality of life despite adequate drug treatment. Many patients experience anxiety, depression, or other psychological disorders. These burdens not only affect patients but also place immense strain on their families and society. The current 5-year survival rate for critically severe patients with PAH receiving optimal drug treatment is only 33.3%. To address these challenges, risk assessment plays a crucial role in guiding the clinicians’ decision-making processes, treatment evaluation, and prognosis prediction for patients with PAH. However, establishing effective risk stratification requires extensive clinical research. High-level clinical research can serve as a means of solving clinical problems and we can gain insights into the process and methods involved. The Chinese PAH cohort represents a unique opportunity to study international experiences in the development of a risk stratification system suitable for the Chinese population. By systematically outlining the development of PAH from its first description as a disease, which garnered attention from the World Health Organization, we appreciate the importance of conducting clinical research that has helped enhance our understanding of this disease. Establishing prognostic prediction equations through clinical studies and conducting international research on risk stratification in the era of targeted drug therapy are vital steps for continuously updating risk stratification guidelines and treatment concepts. The development of high-level clinical research in China can draw inspiration from these processes. By leveraging lessons learned from international experiences, we can pave the way for advancements in PAH research within the country. This included addressing the current application status and challenges faced in the implementation of risk stratification for PAH in China. Future research should focus on refining the risk stratification methods, exploring innovative diagnostic techniques, and identifying novel treatment approaches for PAH. By continuously enhancing our understanding of this complex disease, we can improve patient outcomes and alleviate the burden on individuals, families, and the society as a whole. In conclusion, PAH presents significant challenges in diagnosis, treatment, and risk assessment. By delving into high-level clinical research to address these challenges, we can pave the way for improved management strategies and better outcomes for patients with this devastating condition. Through international collaborations and tailored approaches for the Chinese population, we can strive towards more accurate risk stratification and ultimately enhance the overall care provided to individuals with PAH.

Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan

Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy

Evaluation of Efficacy, Safety and Tolerability of Ambrisentan in Chinese Adults with Pulmonary Arterial Hypertension: a Prospective Open Label Cohort Study

High-level clinical research promotes the development of risk stratification for pulmonary arterial hypertension

Risk stratification and medical therapy of pulmonary arterial hypertension

Clinical Analysis of 150 Patients with Idiopathic Pulmonary Arterial Hypertension

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies

Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective

Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: A COMPERA analysis

Mechanisms and treatment of pulmonary arterial hypertension

Risk stratification and treatment goals in pulmonary arterial hypertension

Pulmonary Hypertension: A Contemporary Review

Pulmonary arterial hypertension: Navigating the pathways of progress in diagnosis, treatment, and patient care

Clinical Characteristics and Factors Associated with Disease Progression in Chinese Patients with Connective Tissue Disease and Pulmonary Arterial Hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Pulmonary Arterial Hypertension.

Pulmonary arterial hypertension: updates and perspective with newer therapies